Annual Report 18/19
Diamyd Medical's Annual Report for the financial year 2018/2019 is now also available in English. The Annual Report is attached as a PDF and is available at www.diamyd.com.
About Us
Diamyd Medical is a clinical-stage diabetes company active in the field of pharmaceutical development. We develop two novel disease-modifying drugs: the antigenspecific immunotherapy Diamyd® and the oral regenerative and immunomodulatory therapeutic Remygen®. A biomanufacturing facility is being set up in Umeå for the manufacture of recombinant GAD65 protein, the active ingredient in the antigen-specific immunotherapy Diamyd®.
Contacts
CEO
Box 7349, SE-103 90 Stockholm
+46 8 661 00 26
+46 8 661 63 68
https://www.diamyd.com
press@diamyd.com
Links
Pick a time period
-
There are no items matching the current filter
There are no more items matching the current filter
Back to top
